Ascendis Pharma A/S filings document foreign private issuer disclosures on Form 6-K, including operating and financial results, clinical and regulatory updates, capital-structure actions and security-structure changes. Recent reports cover TransCon CNP and TransCon hGH data in achondroplasia, the ordinary-share Nasdaq listing that replaced the ADS program, and the exchange of outstanding ADSs into ordinary shares.
The filing record also discloses convertible senior note redemption terms, warrant grants under the company's Articles of Association, registration-statement incorporation by reference, and equity-compensation capacity. Financial disclosures include IFRS reporting items, fair-value and derivative measurements, share capital accounts, treasury shares, and product-related revenue and royalty arrangements.
Ascendis Pharma A/S (ASND) said its outstanding-warrant exercise window closed on September 29, 2026. During the window, the company registered aggregate share capital increases of nominal DKK 210,812 through the issuance of 210,812 ordinary shares against average cash consideration of approximately USD $123.36 per share, based on the DKK-USD exchange rate on September 29, 2026. Its aggregate share capital increased to nominal DKK 66,400,738, and its articles of association were amended accordingly.
Jean Jacques Bienaime, a director of Ascendis Pharma A/S (ASND), agreed to the cancellation of 9,160 warrants granted June 10, 2025, and was awarded a new warrant covering 9,160 underlying Ordinary Shares on April 14, 2026, as part of his board appointment. The cancelled warrant has an exercise price of 172.35 and expires June 10, 2035; it vests 25% on June 10, 2026, followed by 36 equal monthly installments. The new warrant has an exercise price of 249.84 and expires April 14, 2036. It vests 25% on April 14, 2027, followed by 36 equal monthly installments.
Ascendis Pharma A/S (ASND) reports a major change in its collaboration structure with Novo Nordisk A/S. Ascendis announced on September 14, 2026 that it will regain exclusive rights to develop, manufacture, and commercialize TransCon technology-based products in metabolic and cardiovascular diseases, including obesity. This change follows the termination of the prior collaboration agreement between the two companies that was announced in November 2024. Under the termination terms, all licenses granted to Novo Nordisk in these disease areas, including for once-monthly TransCon Semaglutide, revert to Ascendis, and neither party has any continuing financial obligations to the other.
The company also includes extensive forward-looking statement language, highlighting uncertainties around regulatory approvals, clinical development, manufacturing and supply, market acceptance, competition, intellectual property, funding needs, and broader macroeconomic and geopolitical factors that could affect future outcomes related to these regained rights.
Ascendis Pharma A/S (ASND) announced that its board has authorized a share repurchase program of up to $400 million of its ordinary shares. Repurchases may be carried out over time through methods such as open market purchases, privately negotiated transactions, block trades, accelerated share repurchase transactions, and purchases under 10b5-1 trading plans. The company states that the timing and amount of repurchases will depend on market conditions, share price and other factors, and that the program does not obligate Ascendis to repurchase any specific number of shares and may be modified, suspended or terminated at any time without notice.
Ascendis Pharma A/S (ASND) reported Week 52 data from the open-label sentinel cohort of its pivotal reACHin Trial, indicating that once-weekly TransCon CNP (navepegritide) treatment was associated with stabilization or improvement of foramen magnum stenosis and linear growth benefits in infants with achondroplasia aged 0 to <2 years.
The reACHin Trial is a Phase 2, randomized, placebo-controlled study evaluating safety, tolerability, and efficacy of TransCon CNP at a 100 µg/kg/week dose in at least 66 treatment-naïve infants, followed by a 52-week open-label extension. A sentinel cohort of 7 infants (mean age 11.7 months) was first enrolled to assess safety and pharmacokinetics, with outcome measures including Achondroplasia Foramen Magnum Score, change in supine length Z-score, and annualized growth velocity.
Ascendis emphasizes that these results are early and subject to substantial risks and uncertainties, noting that ongoing and future trials, regulatory review, manufacturing, market conditions, and other factors could lead to actual outcomes differing materially from current expectations.
Ascendis Pharma A/S (ASND) reports that SVP & PAO Mads Bodenhoff exercised warrants for 3,000 Ordinary Shares on September 8, 2026 at an exercise price of $110.00 per share and on the same date sold 3,000 Ordinary Shares at $270.19 per share. Following the exercise, 687 warrants remain outstanding, expiring on October 11, 2032, and no Rule 10b5-1 trading plan is reported.
Ascendis Pharma A/S (ASND) reports that its board granted an aggregate of 29,380 warrants to certain employees on September 8, 2026 under Appendix 1a to its Articles of Association. Each warrant entitles the holder to subscribe for one ordinary share at an exercise price of $270.09 per share, equal to the closing market price on the grant date.
Twenty‑five percent of the warrants vest on the one‑year anniversary of grant, with the remaining 75% vesting in equal monthly installments over the following 36 months, subject to continued service, with potential earlier vesting upon certain exit events. After this grant, warrants to subscribe for an additional 1,495,063 shares remain available for future grants under the Articles of Association.
Ascendis Pharma A/S (ASND) has a notice filed on behalf of officer Mads Bodenhoff to sell Ascendis American Depositary Shares under Rule 144. The planned sale covers 3,000 American Depositary Shares, with an stated aggregate market value of 810,562.66, to be effected through Merrill Lynch on or after September 8, 2026 following a warrant exercise for cash.
Ascendis Pharma A/S (ASND) director Lars Holtug reported selling 236 Ordinary Shares on September 2, 2026 in an open-market or private transaction at $264.13 per share. After this sale, he directly holds 4,000 Ordinary Shares of Ascendis Pharma A/S.
No Rule 10b5-1 trading plan is reported for this transaction.
Ascendis Pharma A/S (ASND) is the issuer for a planned resale of 236 ordinary shares under Rule 144 for the account of director Lars Holtugcompensation-related shares to cover income tax obligations, with Citigroup Global Markets as the broker.